Digest Network Come funziona
Network
/
Società
Mo
Non verificato

Modalis Therapeutics Corporation

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaSaluteVetrine/Shopping

5 comunicati stampa

Guarda tutti i comunicati
25/12/2025
Salute
Vetrine/Shopping
Biotecnologia
Assistenza all'Infanzia
Farmaceutica
Industria
Modalis Announces Publication in Human Gene Therapy of Study Demonstrating Efficient LAMA1 Gene Activation for the Treatment of LAMA2-CMD
Fonte
Modalis Therapeutics Corporation
Emittente
Business Wire
1.00
0
12/05/2025
Eventi
Appalti e gare
Scienza
Giovani
Biotecnologia
Medicina - Varie
Farmaceutica
Vetrine/Shopping
Salute
Modalis has been selected as a finalist in the XPRIZE Healthspan FSHD Bonus Prize Competition and awarded research funds.
Fonte
Modalis Therapeutics Corporation
Emittente
Business Wire
1.00
0
06/01/2025
Multimedialità
Mercato del lavoro
Industria
Biotecnologia
Salute
Farmaceutica
JCR Pharmaceuticals and Modalis Therapeutics Announce Transition to the Next Phase of Joint Research Agreement for Development of Novel Gene Therapy
Fonte
Modalis Therapeutics Corporation
Emittente
Business Wire
1.00
0
25/10/2024
Industria
Scienza
Biotecnologia
Farmaceutica
Salute
Igiene alimentare
Modalis Therapeutics has received an Orphan Drug Designation from the U.S. Food and Drug Administration for MDL-101, a treatment for congenital muscular dystrophy type 1A (LAMA2-CMD).
Fonte
Modalis Therapeutics Corporation
Emittente
Business Wire
1.00
0
30/09/2024
Industria
Salute
Igiene alimentare
Vetrine/Shopping
Biotecnologia
Infanzia
Farmaceutica
Modalis Therapeutics: FDA Grants Rare Pediatric Disease Designation to MDL-101 for the Treatment of Congenital Muscular Dystrophy Type 1a (LAMA2-CMD)
Fonte
Modalis Therapeutics Corporation
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0